Dyadic announces continued progress towards commercialization of animal-free recombinant serum albumin

Jupiter, fla., aug. 07, 2023 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company's animal-free recombinant serum albumin.
DYAI Ratings Summary
DYAI Quant Ranking